Pharmadrug Inc.
PHRX
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -96.80% | -95.45% | -95.02% | -63.91% | 47.44% |
| Depreciation & Amortization | -23.40% | -4.50% | 26.57% | 90.16% | 7,933.33% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -85.37% | -85.01% | -88.62% | -57.05% | 37.30% |
| Operating Income | 85.37% | 85.01% | 88.62% | 57.05% | -37.30% |
| Income Before Tax | 97.98% | 97.34% | 96.99% | 93.86% | -1,065.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 97.83% | 97.14% | 96.76% | 93.40% | -894.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -9.87% | -2.64% | 10.18% | 136.97% | -- |
| Net Income | 98.69% | 97.99% | 97.60% | 94.46% | -1,032.06% |
| EBIT | 85.37% | 85.01% | 88.62% | 57.05% | -37.30% |
| EBITDA | 89.00% | 88.36% | 91.53% | 60.25% | -32.25% |
| EPS Basic | 99.15% | 98.64% | 98.33% | 95.89% | -696.91% |
| Normalized Basic EPS | 89.53% | 87.00% | 87.30% | 72.87% | -22.86% |
| EPS Diluted | 99.15% | 98.64% | 98.33% | 95.90% | -732.90% |
| Normalized Diluted EPS | 89.53% | 87.00% | 87.30% | 72.87% | -22.86% |
| Average Basic Shares Outstanding | 15.82% | 33.87% | 55.54% | 80.22% | 84.18% |
| Average Diluted Shares Outstanding | 15.82% | 33.87% | 55.54% | 80.22% | 84.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |